Latest Period
Q1 2026
Security Snapshot
Revolution Medicines, Inc. - Common Stock (RVMD) Institutional Ownership
CUSIP: 76155X100
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
505
Shares (Excl. Options)
195,858,704
Price
$97.25
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- RVMD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 195,858,704
- Total 13F value
- $19,031,369,309
- Portfolio coverage rank
- 0.04%
- Share change
- -3,746,254
- Value change
- -$293,491,424
- Number of holders
- 505
- Shares outstanding
- 199,316,245
- SEC-reported price per share
- $145.72
- Insider filing price
- $145.72
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RVMD - Revolution Medicines, Inc. - Common Stock is tracked under CUSIP 76155X100.
- 505 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 385 to 505 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $15,874,866,294 to $19,031,369,309.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 505 institutions filings for Q1 2026.
Security key
76155X100
Latest holder period
Q1 2026
13F holders
505
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
RVMD full holder history
Revolution Medicines, Inc. SEC filings
Revolution Medicines, Inc. company facts
Revolution Medicines, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 76155X100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RVMD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 7.5% | -5% | $1,499,170,464 | +$137,025,822 | 14,596,149 | +10% | Dapice Joshua J. | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC | 4.9% | -20% | $963,367,165 | -$156,794,001 | 9,766,496 | -14% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP | 4.9% | -2% | $971,159,717 | +$9,283,443 | 9,455,357 | +0.97% | Baker Bros. Advisors LP | 31 Dec 2025 |
| FMR LLC | 5% | $439,058,769 | 9,401,687 | FMR LLC | 30 Sep 2025 | |||
| BlackRock, Inc. | 4.5% | $309,009,603 | 8,399,214 | BlackRock, Inc. | 30 Jun 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 3.6% | -32% | $717,700,402 | -$336,077,288 | 6,987,639 | -32% | Wellington Management Group LLP | 31 Dec 2025 |
As of 31 Mar 2026, 505 institutional investors reported holding 195,858,704 shares of Revolution Medicines, Inc. - Common Stock (RVMD). This represents 98% of the company’s total 199,316,245 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 6.8% | 13,604,796 | -6.7% | 8.6% | $1,323,066,411 |
| BlackRock, Inc. | 5.6% | 11,212,706 | +26% | 0.02% | $1,090,435,565 |
| JANUS HENDERSON GROUP PLC | 4.9% | 9,766,496 | -21% | 0.45% | $949,537,126 |
| BAKER BROS. ADVISORS LP | 4.8% | 9,555,357 | +1.1% | 5.3% | $929,258,468 |
| FMR LLC | 4.2% | 8,464,314 | -1.4% | 0.04% | $823,154,497 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 8,362,284 | 0% | 0.02% | $813,232,119 |
| Nextech Invest, Ltd. | 3.8% | 7,601,087 | 0% | 52% | $739,205,711 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8% | 7,502,623 | 0% | 0.04% | $729,630,087 |
| Paradigm Biocapital Advisors LP | 3.3% | 6,655,703 | +0.17% | 13% | $647,267,117 |
| WELLINGTON MANAGEMENT GROUP LLP | 3% | 6,027,819 | -14% | 0.11% | $586,205,399 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.7% | 5,475,611 | +148% | 0.82% | $532,503,170 |
| STATE STREET CORP | 2.2% | 4,402,662 | +7.1% | 0.01% | $428,158,880 |
| UBS Group AG | 2.2% | 4,386,791 | +42% | 0.08% | $426,615,425 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 3,338,142 | +5.6% | 0.02% | $323,930,219 |
| Alphabet Inc. | 1.7% | 3,292,525 | -1.6% | 8% | $320,198,056 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 3,232,213 | -5.1% | 0.04% | $314,333,000 |
| BVF INC/IL | 1.4% | 2,856,782 | -15% | 8.9% | $277,822,050 |
| Casdin Capital, LLC | 1.3% | 2,577,333 | 0% | 19% | $250,645,634 |
| Woodline Partners LP | 1.3% | 2,506,570 | +0.23% | 0.92% | $243,763,933 |
| Holocene Advisors, LP | 1.2% | 2,468,644 | +29% | 0.58% | $240,075,629 |
| Vestal Point Capital, LP | 1.2% | 2,375,000 | +705% | 6.5% | $230,968,750 |
| Avoro Capital Advisors LLC | 1.2% | 2,344,444 | +8% | 2.2% | $227,997,179 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.2% | 2,297,000 | -21% | 2.6% | $223,383,250 |
| Darwin Global Management, Ltd. | 1.1% | 2,211,018 | 5.4% | $204,983,479 | |
| GOLDMAN SACHS GROUP INC | 1.1% | 2,185,500 | -12% | 0.03% | $212,539,875 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q1 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 195,858,704 | $19,031,369,309 | -$293,491,424 | $97.25 | 505 |
| 2025 Q4 | 199,291,356 | $15,874,866,294 | +$489,477,380 | $79.65 | 385 |
| 2025 Q3 | 191,767,706 | $8,955,119,353 | +$87,454,891 | $46.70 | 318 |
| 2025 Q2 | 190,726,235 | $7,017,009,498 | -$4,134,347 | $36.79 | 305 |
| 2025 Q1 | 191,051,347 | $6,776,444,446 | -$111,943,197 | $35.36 | 281 |
| 2024 Q4 | 193,048,484 | $8,445,124,761 | +$672,301,180 | $43.74 | 278 |
| 2024 Q3 | 170,577,261 | $7,735,337,873 | +$69,484,732 | $45.35 | 252 |
| 2024 Q2 | 168,410,110 | $6,536,274,916 | +$309,463,084 | $38.81 | 221 |
| 2024 Q1 | 160,549,965 | $5,174,502,235 | +$41,971,613 | $32.23 | 207 |
| 2023 Q4 | 159,991,814 | $4,588,662,174 | +$1,173,667,984 | $28.68 | 183 |
| 2023 Q3 | 112,410,338 | $3,111,480,815 | +$13,449,543 | $27.68 | 165 |
| 2023 Q2 | 111,960,439 | $2,994,417,481 | +$107,072,959 | $26.75 | 138 |
| 2023 Q1 | 108,245,336 | $2,343,498,970 | +$420,665,649 | $21.66 | 149 |
| 2022 Q4 | 88,251,337 | $2,102,174,977 | +$32,658,345 | $23.82 | 133 |
| 2022 Q3 | 88,392,782 | $1,743,047,001 | +$233,806,685 | $19.72 | 133 |
| 2022 Q2 | 76,461,750 | $1,490,187,152 | +$40,971,035 | $19.49 | 125 |
| 2022 Q1 | 73,955,592 | $1,885,584,241 | +$15,751,102 | $25.51 | 122 |
| 2021 Q4 | 73,332,089 | $1,845,795,329 | -$50,104,402 | $25.17 | 113 |
| 2021 Q3 | 68,952,735 | $1,896,915,710 | +$49,809,012 | $27.51 | 109 |
| 2021 Q2 | 70,364,140 | $2,233,248,707 | +$91,598,352 | $31.74 | 127 |
| 2021 Q1 | 66,456,882 | $3,048,913,145 | +$424,322,383 | $45.88 | 124 |
| 2020 Q4 | 57,426,011 | $2,273,517,142 | +$133,648,027 | $39.59 | 118 |
| 2020 Q3 | 56,953,834 | $1,981,075,717 | +$339,721,674 | $34.80 | 90 |
| 2020 Q2 | 46,886,789 | $1,478,128,925 | +$22,763,370 | $31.57 | 73 |
| 2020 Q1 | 46,881,176 | $1,025,119,285 | +$1,024,845,284 | $21.91 | 72 |